UCL Therapeutic Innovation Networks


The Development of Gene Therapy for Infantile Neuroaxonal Dystrophy

In this interview, Dr Ahad Rahim describes his translational project developing gene therapy for INAD and how the UCL TRO have provided support to overcome usual advanced therapy bottlenecks.

Ahad Rahim headshot

14 May 2020

Dr Ahad Rahim is an Associate Professor of Translational Neuroscience and Associate Director of Research at the UCL School of Pharmacy. Dr Rahim’s group works on the development of novel therapies for neurodegenerative diseases and recently at the end of 2019, received an MRC DPFS grant of £654,904 to develop gene therapy for infantile neuroaxonal dystrophy (INAD).

Read the full interview on the UCL TRO blog